SK288113B6 - Aqueous, sterile, ready-to-use pharmaceutical composition comprising esmolol hydrochloride and method for its preparation - Google Patents

Aqueous, sterile, ready-to-use pharmaceutical composition comprising esmolol hydrochloride and method for its preparation Download PDF

Info

Publication number
SK288113B6
SK288113B6 SK1278-2002A SK12782002A SK288113B6 SK 288113 B6 SK288113 B6 SK 288113B6 SK 12782002 A SK12782002 A SK 12782002A SK 288113 B6 SK288113 B6 SK 288113B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
solution
sterile pharmaceutical
hydrochloride
sodium
Prior art date
Application number
SK1278-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK12782002A3 (sk
Inventor
Jie Liu
Satish K. Pejaver
George Owoo
Original Assignee
Baxter International Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26688377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288113(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/759,547 external-priority patent/US6310094B1/en
Application filed by Baxter International Inc. filed Critical Baxter International Inc.
Publication of SK12782002A3 publication Critical patent/SK12782002A3/sk
Publication of SK288113B6 publication Critical patent/SK288113B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
SK1278-2002A 2001-01-12 2002-01-02 Aqueous, sterile, ready-to-use pharmaceutical composition comprising esmolol hydrochloride and method for its preparation SK288113B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/759,547 US6310094B1 (en) 2001-01-12 2001-01-12 Ready-to-use esmolol solution
US10/016,260 US6528540B2 (en) 2001-01-12 2001-10-30 Esmolol formulation
PCT/US2002/000329 WO2002076446A1 (en) 2001-01-12 2002-01-02 Esmolol formulation

Publications (2)

Publication Number Publication Date
SK12782002A3 SK12782002A3 (sk) 2003-11-04
SK288113B6 true SK288113B6 (sk) 2013-08-02

Family

ID=26688377

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1278-2002A SK288113B6 (sk) 2001-01-12 2002-01-02 Aqueous, sterile, ready-to-use pharmaceutical composition comprising esmolol hydrochloride and method for its preparation

Country Status (21)

Country Link
EP (1) EP1368019B2 (de)
JP (1) JP2004519506A (de)
CN (1) CN1298320C (de)
AT (1) ATE341319T1 (de)
AU (1) AU2002309475B2 (de)
BR (1) BR0203517A (de)
CA (1) CA2410446C (de)
CZ (1) CZ304290B6 (de)
DE (1) DE60215129T3 (de)
DK (1) DK1368019T4 (de)
ES (1) ES2272720T5 (de)
HU (1) HUP0204520A3 (de)
IL (1) IL151359A (de)
MX (1) MXPA03006229A (de)
PL (1) PL216192B1 (de)
RU (1) RU2286774C2 (de)
SI (1) SI1368019T2 (de)
SK (1) SK288113B6 (de)
TR (1) TR200202557T1 (de)
TW (1) TWI277414B (de)
WO (1) WO2002076446A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
EP1417962A1 (de) 2002-11-06 2004-05-12 AOP Orphan Pharmaceuticals AG Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
CN1303987C (zh) * 2004-11-19 2007-03-14 陈庆财 注射用盐酸艾司洛尔冻干粉针剂及其制备方法
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
AU2014203121B2 (en) * 2007-05-22 2016-04-21 Baxter Healthcare Sa Concentrate esmolol
JP5623288B2 (ja) 2007-12-21 2014-11-12 エイオーピーオーファン ファーマスーティカルズ アクチエンゲゼルシャフトAOP Orphan Pharmaceuticals Aktiengesellschaft 医薬組成物
DK2480204T3 (da) * 2009-09-22 2014-02-03 Vlife Sciences Technologies Pvt Ltd Topikal formulering til diabetiske fodsår
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
US8686036B2 (en) 2011-01-27 2014-04-01 Baxter International Inc. Methods of controlling heart rate while minimizing and/or controlling hypotension
JP2014511365A (ja) 2011-01-27 2014-05-15 バクスター・インターナショナル・インコーポレイテッド 心臓障害の処置に関連する静脈刺激を調節するための(s)−エスモロールの使用
EP2846776B1 (de) 2012-05-10 2020-04-15 AOP Orphan Pharmaceuticals AG Parenterale esmololformulierung
US8835505B1 (en) 2013-03-15 2014-09-16 Welgrace Research Group Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
CN104473869A (zh) * 2014-11-20 2015-04-01 北京京科泰来科技有限公司 一种艾司洛尔脂肪乳及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857552A (en) * 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
CN1074763C (zh) * 1997-11-13 2001-11-14 山东省医药工业研究所 艾司洛尔盐酸盐的制备方法

Also Published As

Publication number Publication date
DE60215129T2 (de) 2007-02-15
CZ20023825A3 (cs) 2003-02-12
HUP0204520A2 (en) 2003-05-28
CZ304290B6 (cs) 2014-02-19
PL357387A1 (en) 2004-07-26
TR200202557T1 (tr) 2003-06-23
SK12782002A3 (sk) 2003-11-04
CA2410446A1 (en) 2002-10-03
CN1455669A (zh) 2003-11-12
IL151359A (en) 2009-09-01
WO2002076446A1 (en) 2002-10-03
BR0203517A (pt) 2003-06-03
EP1368019A1 (de) 2003-12-10
CA2410446C (en) 2008-08-26
RU2286774C2 (ru) 2006-11-10
EP1368019B1 (de) 2006-10-04
ES2272720T3 (es) 2007-05-01
AU2002309475B2 (en) 2006-08-03
ATE341319T1 (de) 2006-10-15
CN1298320C (zh) 2007-02-07
RU2002132189A (ru) 2004-03-27
TWI277414B (en) 2007-04-01
HUP0204520A3 (en) 2004-12-28
SI1368019T1 (sl) 2007-02-28
ES2272720T5 (es) 2010-10-25
DK1368019T3 (da) 2006-12-11
JP2004519506A (ja) 2004-07-02
DE60215129T3 (de) 2010-09-09
DE60215129D1 (de) 2006-11-16
MXPA03006229A (es) 2004-05-24
DK1368019T4 (da) 2010-07-19
SI1368019T2 (sl) 2010-10-29
EP1368019B2 (de) 2010-06-02
IL151359A0 (en) 2003-04-10
PL216192B1 (pl) 2014-03-31

Similar Documents

Publication Publication Date Title
JP5778384B2 (ja) エスモロール処方物
SK288113B6 (sk) Aqueous, sterile, ready-to-use pharmaceutical composition comprising esmolol hydrochloride and method for its preparation
US20150005376A1 (en) Concentrate esmolol
EP2162154B1 (de) Farbige esmolol-konzentrate
AU2008256949B2 (en) Multi-dose concentrate esmolol with benzyl alcohol
AU2014203121B2 (en) Concentrate esmolol

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20190102